JAK2 and myeloproliferative neoplasm: However, our data convincingly show that JAK/PIM combination not only enhances the efficacy of JAK2 inhibitors in “naïve” MPN cells, but can also eradicates MPN cells that have become resistant to JAK2 monotherapy The increased MYC protein levels observed in the resistant cells described in this work might be the underlying or a contributing resistance mechanism, and MYC destabilization via PIM inhibition a means to resensitize these cells to JAK2 inhibition.